热门出版物 - 学术资源搜索

h5 指数:69
h5 中位数:98

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#14 Gastroenterology & Hepatology

标题/作者	引用次数	年份
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications C Maaser, A Sturm, SR Vavricka, T Kucharzik, G Fiorino, V Annese, ... Journal of Crohn's and Colitis 13 (2), 144-164K	910	2019
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment J Torres, S Bonovas, G Doherty, T Kucharzik, JP Gisbert, T Raine, ... Journal of Crohn's and Colitis 14 (1), 4-22	747	2020
ECCO-ESCP Consensus on Surgery for Crohn’s Disease WA Bemelman, J Warusavitarne, GM Sampietro, Z Serclova, O Zmora, ... Journal of Crohn's and Colitis 12 (1), 1-16	336	2018
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment M Adamina, S Bonovas, T Raine, A Spinelli, J Warusavitarne, A Armuzzi, ... Journal of Crohn's and Colitis 14 (2), 155-168	314	2020
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update PF van Rheenen, M Aloi, A Assa, J Bronsky, JC Escher, UL Fagerberg, ... Journal of Crohn's and Colitis 15 (2), 171-194	305	2021
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects A Sturm, C Maaser, E Calabrese, V Annese, G Fiorino, T Kucharzik, ... Journal of Crohn's and Colitis 13 (3), 273-284	245	2019
Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1 L Zhou, M Zhang, Y Wang, T Yu, X Chen, D Tang, L Xu, Y Yin, Y Pan, ... JOURNAL OF CROHNS & COLITIS 12, S110-S111	242	2018
Inclusion of the Mesentery in Ileocolic Resection for Crohn’s Disease is Associated With Reduced Surgical Recurrence CJ Coffey, MG Kiernan, SM Sahebally, A Jarrar, JP Burke, PA Kiely, ... Journal of Crohn's and Colitis 12 (10), 1139-1150	218	2018
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection? G Monteleone, S Ardizzone Journal of Crohn's and Colitis 14 (9), 1334-1336	212	2020
Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib KL Winthrop, GY Melmed, S Vermeire, MD Long, G Chan, RD Pedersen, ... JOURNAL OF CROHNS & COLITIS 12, S364-S364	195	2018
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment T Raine, S Bonovas, J Burisch, T Kucharzik, M Adamina, V Annese, ... Journal of Crohn's and Colitis 16 (1), 2-17	181	2022
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review JF Colombel, G D’haens, WJ Lee, J Petersson, R Panaccione Journal of Crohn's and Colitis 14 (2), 254-266	180	2020
European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease G Doherty, KH Katsanos, J Burisch, M Allez, K Papamichael, A Stallmach, ... Journal of Crohn's and Colitis 12 (1), 17-31	168	2018
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis S Singh, J George, BS Boland, N Vande Casteele, WJ Sandborn Journal of Crohn's and Colitis 12 (6), 635-643	158	2018
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease SB Hanauer, WJ Sandborn, BG Feagan, C Gasink, D Jacobstein, B Zou, ... Journal of Crohn's and Colitis 14 (1), 23-32	157	2020
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease T Kucharzik, P Ellul, T Greuter, JF Rahier, B Verstockt, C Abreu, ... Journal of Crohn's and Colitis 15 (6), 879-913	149	2021
Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis M Zhang, C Xu, D Liu, MK Han, L Wang, D Merlin Journal of Crohn's and Colitis 12 (2), 217-229	146	2018
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study VBC Biemans, AE van der Meulen-de Jong, CJ van der Woude, ... Journal of Crohn's and Colitis 14 (1), 33-45	133	2020
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice JP Gisbert, M Chaparro Journal of Crohn's and Colitis 14 (5), 694-709	130	2020
Characteristics of Faecal Microbiota in Paediatric Crohn’s Disease and Their Dynamic Changes During Infliximab Therapy Y Wang, X Gao, A Ghozlane, H Hu, X Li, Y Xiao, D Li, G Yu, T Zhang Journal of Crohn's and Colitis 12 (3), 337-346	129	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。